Renal cell carcinoma
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Summary
Bevacizumab, sorafenib and temsirolimus are not recommended as first drug treatments for people with advanced and/or metastatic renal cell carcinoma. Sorafenib and sunitinib are not recommended as second drug treatments for people with advanced and/or metastatic renal cell carcinoma. Specialists s ...
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in June 2011
About this guidance
Technology appraisals TA178
Issued: August 2009
How this guidance was produced